Bafna Pharmaceuticals Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 422.44 million compared to INR 149.82 million a year ago. Revenue was INR 425.02 million compared to INR 162.13 million a year ago. Net income was INR 53.72 million compared to net loss of INR 9.5 million a year ago. Basic earnings per share from continuing operations was INR 2.34 compared to basic loss per share from continuing operations of INR 0.36 a year ago. Diluted earnings per share from continuing operations was INR 2.34 compared to diluted loss per share from continuing operations of INR 0.36 a year ago.
For the full year, sales was INR 1,153.5 million compared to INR 851.4 million a year ago. Revenue was INR 1,186.23 million compared to INR 868.38 million a year ago. Net income was INR 113.38 million compared to INR 52.16 million a year ago. Basic earnings per share from continuing operations was INR 4.86 compared to INR 2.19 a year ago. Diluted earnings per share from continuing operations was INR 4.86 compared to INR 2.19 a year ago.